Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials. METHODS: We searched PubMed, MEDLINE, The Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from Jan 1, 1966, to Sept 1, 2019, to identify potentially eligible randomised controlled trials. Eligible studies were randomised controlled trials comparing one blood pressure lowering drug class with a placebo, inactive control, or other blood pressure lowering drug. We also required that trials had at least 1000 participant years of follow-up in each treatment group. Trials without cancer event information were excluded. We requested individual participant data from the authors of eligible trials. We pooled individual participant-level data from eligible trials and assessed the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), β blockers, calcium channel blockers, and thiazide diuretics on cancer risk in one-stage individual participant data and network meta-analyses. Cause-specific fixed-effects Cox regression models, stratified by trial, were used to calculate hazard ratios (HRs). The primary outcome was any cancer event, defined as the first occurrence of any cancer diagnosed after randomisation. This study is registered with PROSPERO (CRD42018099283). FINDINGS: 33 trials met the inclusion criteria, and included 260 447 participants with 15 012 cancer events. Median follow-up of included participants was 4·2 years (IQR 3·0-5·0). In the individual participant data meta-analysis comparing each drug class with all other comparators, no associations were identified between any antihypertensive drug class and risk of any cancer (HR 0·99 [95% CI 0·95-1·04] for ACEIs; 0·96 [0·92-1·01] for ARBs; 0·98 [0·89-1·07] for β blockers; 1·01 [0·95-1·07] for thiazides), with the exception of calcium channel blockers (1·06 [1·01-1·11]). In the network meta-analysis comparing drug classes against placebo, we found no excess cancer risk with any drug class (HR 1·00 [95% CI 0·93-1·09] for ACEIs; 0·99 [0·92-1·06] for ARBs; 0·99 [0·89-1·11] for β blockers; 1·04 [0·96-1·13] for calcium channel blockers; 1·00 [0·90-1·10] for thiazides). INTERPRETATION: We found no consistent evidence that antihypertensive medication use had any effect on cancer risk. Although such findings are reassuring, evidence for some comparisons was insufficient to entirely rule out excess risk, in particular for calcium channel blockers. FUNDING: British Heart Foundation, National Institute for Health Research, Oxford Martin School.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Self-citationDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Self-citationIntroduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142
Self-citationPatel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
Self-citation
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationMartin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Self-citationMartin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Self-citationRahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Wamil, M., Majert, J., McManus, R., Adler, A., Agodoa, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01921-8 · Cited by 338
Self-citation
Metadata
- Authors
- Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., Kjeldsen, S., Sundström, J., Rahimi, K., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N., Berge, E., Black, H., Brouwers, F. P. J., Brown, M., Bulpitt, C. J., Byington, B., Chalmers, J., Cushman, W. C., Cutler, J., Davis, B. R., Devereaux, R. B., Dwyer, J., Estacio, R., Fagard, R., Fox, K., Fukui, T., Gupta, A. K., Holman, R. R., Imai, Y., Ishii, M., Julius, S., Kanno, Y., Kjeldsen, S. E., Kostis, J., Kuramoto, K., Lanke, J., Lewis, E., Lewis, J., Lievre, M., Lindholm, L. H., Lueders, S., MacMahon, S., Mancia, G., Matsuzaki, M., Mehlum, M. H., Nissen, S., Ogawa, H., Ogihara, T., Ohkubo, T., Palmer, C., Patel, A., Pepine, C. J., Pfeffer, M., Poulter, N. R., Rakugi, H., Reboldi, G., Reid, C., Remuzzi, G., Ruggenenti, P., Saruta, T., Schrader, J., Schrier, R., Sever, P., Sleight, P., Staessen, J. A., Suzuki, H., Thijs, L., Ueshima, K., Umemoto, S., van Gilst, W. H., Verdecchia, P., Wachtell, K., Whelton, P., Wing, L., Woodward, M., Yui, Y., Yusuf, S., Zanchetti, A., Zhang, Z. Y., Anderson, C., Baigent, C., Brenner, B., Collins, R., de Zeeuw, D., Lubsen, J., Malacco, E., Neal, B., Perkovic, V, Pitt, B., Rodgers, A., Rothwell, P., Salimi-Khorshidi, G., Sundström, J., Turnbull, F., Viberti, G., & Wang, J.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 22
- Issue
- 4
- Pages
- 558-570
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3145416765
- Cited by
- 103
- References
- 19
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00033-4
- The paper
- Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., Kjeldsen, S., Sundström, J., Rahimi, K., Adler, A., Agodoa, L., Algra, A., Asselbergs, F. W., Beckett, N., Berge, E., . . . Wang, J. (2021). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00033-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.